Latest Nasdaq Delisting News

Almonty Industries will delist from the Toronto Stock Exchange by July 31, 2026, focusing its trading exclusively on Nasdaq to streamline costs and align with where most activity occurs.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Light & Wonder, Inc. has amended its credit agreement to introduce a new $2.13 billion tranche of term loans due in 2029, replacing prior debt and reducing borrowing costs. The move reflects a strategic refinancing amid its Nasdaq delisting process.

Light & Wonder, Inc. is set to extend its substantial share repurchase program to include its ASX-listed CHESS Depositary Interests starting November 7, 2025, coinciding with its planned Nasdaq delisting.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Light & Wonder reported solid Q2 earnings growth and margin expansion despite slight revenue dip, completed Grover acquisition ahead of schedule, and announced plans to delist from Nasdaq for a sole ASX listing by November 2025.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.